Micro and nanoparticle drug delivery systems for preventing allotransplant rejection.
Micro and nanoparticle drug delivery systems for preventing allotransplant rejection.
复制标题
DOI：
10.1016/j.clim.2015.04.013
复制
发表时间：
2015-09
期刊：
影响因子：
--
通讯作者：
Little SR
中科院分区：
文献类型：
--
作者：
Fisher JD;Acharya AP;Little SR
尽管移植免疫学已经取得了几十年的进展，但急性同种异体移植排斥反应引起的组织损伤仍然是移植受者发病和死亡的主要原因。此外，终身免疫抑制的长期后遗症使患者面临发展出许多其他有害疾病的风险。使用微纳米颗粒（MNPs）控制药物递送是一种有效的方法，可以将较高的局部剂量的给定药物递送到特定的组织和细胞，同时减轻全身效应。在此，我们回顾了几种旨在延长同种异体移植物存活的MNP免疫疗法的描述。我们还讨论了利用MNP结构诱导和招募人体自身抑制性免疫细胞的仿生药物递送领域的进展。最后，我们评论了与这些药物输送系统相关的调控途径。总之，我们希望本综述中描述的研究将有助于开创器官移植免疫治疗的新时代。
Despite decades of advances in transplant immunology, tissue damage caused by acute allograft rejection remains the primary cause of morbidity and mortality in the transplant recipient. Moreover, the long-term sequelae of lifelong immunosuppression leaves patients at risk for developing a host of other deleterious conditions. Controlled drug delivery using micro- and nanoparticles (MNPs) is an effective way to deliver higher local doses of a given drug to specific tissues and cells while mitigating systemic effects. Herein, we review several descriptions of MNP immunotherapies aimed at prolonging allograft survival. We also discuss developments in the field of biomimetic drug delivery that use MNP constructs to induce and recruit our bodies' own suppressive immune cells. Finally, we comment on the regulatory pathway associated with these drug delivery systems. Collectively, it is our hope the studies described in this review will help to usher in a new era of immunotherapy in organ transplantation.